Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination…
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients…